WO2014020205A3 - Inmunógenos anti-vih mejorados - Google Patents

Inmunógenos anti-vih mejorados Download PDF

Info

Publication number
WO2014020205A3
WO2014020205A3 PCT/ES2013/070539 ES2013070539W WO2014020205A3 WO 2014020205 A3 WO2014020205 A3 WO 2014020205A3 ES 2013070539 W ES2013070539 W ES 2013070539W WO 2014020205 A3 WO2014020205 A3 WO 2014020205A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
agents
host
improved anti
concept
Prior art date
Application number
PCT/ES2013/070539
Other languages
English (en)
French (fr)
Other versions
WO2014020205A2 (es
Inventor
Francisco CONEJERO LARA
Irene LUQUE FERNÁNDEZ
Pedro Luis MATEO ALARCÓN
Raphaelle El Habib
Original Assignee
Universidad De Granada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad De Granada filed Critical Universidad De Granada
Publication of WO2014020205A2 publication Critical patent/WO2014020205A2/es
Publication of WO2014020205A3 publication Critical patent/WO2014020205A3/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere en general al campo de la inmunología y, en particular, a agentes y composiciones adecuados para la administración a un huésped, inmunizando y generando de ese modo protección del huésped frente a infección y enfermedad por VIH. Los agentes de la invención son variantes mejoradas de polipéptidos de gp41. Los inventores proporcionan el concepto general de que una disminución en la temperatura de desnaturalización es indicativa de una exposición superior de epítopos en polipéptidos derivados de gp41. Los polipéptidos de la invención también pueden mostrar una solubilidad superior a pH fisiológico. La invención también proporciona ejemplos específicos de los agentes de la invención, tal como polipéptidos específicos que tienen una secuencia de aminoácidos definida. Estos polipéptidos específicos demuestran el concepto de la invención.
PCT/ES2013/070539 2012-07-31 2013-07-23 Inmunógenos anti-vih mejorados WO2014020205A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12382310.6 2012-07-31
EP12382310 2012-07-31

Publications (2)

Publication Number Publication Date
WO2014020205A2 WO2014020205A2 (es) 2014-02-06
WO2014020205A3 true WO2014020205A3 (es) 2014-04-17

Family

ID=46785346

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2013/070539 WO2014020205A2 (es) 2012-07-31 2013-07-23 Inmunógenos anti-vih mejorados

Country Status (1)

Country Link
WO (1) WO2014020205A2 (es)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053587A2 (fr) * 2001-01-05 2002-07-11 Aventis Pasteur Polypeptide induisant des anticorps neutralisant le vih
WO2010114628A2 (en) * 2009-04-03 2010-10-07 Duke University Formulation for inducing broadly reactive neutralizing anti-hiv antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053587A2 (fr) * 2001-01-05 2002-07-11 Aventis Pasteur Polypeptide induisant des anticorps neutralisant le vih
WO2010114628A2 (en) * 2009-04-03 2010-10-07 Duke University Formulation for inducing broadly reactive neutralizing anti-hiv antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KRELL, T. ET AL.: "HIV-1 gp41 and gp 160 are hyperthermostable proteins in a mesophilic environment", EUR. J. BIOCHEM., vol. 271, no. 8, April 2004 (2004-04-01), pages 1566 - 1579 *
SANDERS, R.W. ET AL.: "Mutational analyses and natural variability of the gp41 ectodomain", 2002, pages I-23 - I-47, Retrieved from the Internet <URL:http://www.hiv.lanl.gov/content/immunology/pdf/2002/1/Sanders2002.pdf> [retrieved on 20131227] *

Also Published As

Publication number Publication date
WO2014020205A2 (es) 2014-02-06

Similar Documents

Publication Publication Date Title
WO2012065963A3 (en) Antiviral condensed heterocyclic compounds
NZ709260A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EA202090675A3 (ru) Стабилизированные растворимые f-полипептиды rsv до слияния
BR112013025221A8 (pt) retenção de moléculas de ligação a antígeno em plasma sanguíneo e método para modificação de imunogenicidade
MX2017007814A (es) Compuesto de carbamoilpiridona policiclicos y su uso farmaceutico.
EA201490774A1 (ru) Новые производные оксазина и их применение при лечении заболевания
MD4602B1 (ro) Inhibitori ai virusului hepatic C
WO2012168431A3 (en) Polypeptides
WO2012021715A3 (en) Stable formulations of linaclotide
MX2015007563A (es) Composiciones farmaceuticas.
WO2011109511A3 (en) Novel hiv-1 envelope glycoprotein
EP2873423A3 (en) Soluble hiv-1 envelope glycoprotein trimers
EA201490610A1 (ru) Соединения и способы усиления врожденных иммунных ответов
WO2013110818A3 (en) Immunogens for hiv vaccination
EA201290956A1 (ru) Вакцина против вич
WO2014160747A3 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
EA201490213A1 (ru) Бензофурановые соединения для лечения инфекций вирусом гепатита с
MX2014014682A (es) Glicoproteina 120 (gp120) estabilizada.
WO2013181339A3 (en) Cyclosporin a analogs
UA117154C2 (uk) Антагоністи s1p3
EA201491969A1 (ru) Иммуногенные соединения, включающие пептид gp41 вич, связанный с белком-носителем crm197
EA201590078A1 (ru) Вакцина против пневмонии, вызываемой streptococcus pneumoniae, на основе гибридного белка
WO2012116142A3 (en) Combined cell based gp96-ig-siv/hiv, recombinant gp120 protein vaccination for protection from siv/hiv
BRPI1008815A2 (pt) composições farmacêuticas compreendendo peptídeos inibidores de tgf-beta1
JP2015517484A5 (es)

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 13825013

Country of ref document: EP

Kind code of ref document: A2